GlassScriptPhysician profile
Toni H Bowyer
NPI 1003847286
$4,111.82
in general payments reported to CMS, 2019-2025
27 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $406 · 2022: $723 · 2023: $606 · 2024: $988 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,948 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,947.87 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,039.36 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $845.31 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Pfizer INC. | $269.67 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $204.82 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.75 | 2021-2025 | Hyqvia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $173.73 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $164.89 | 2022-2025 | Adbry |
| Glaxosmithkline, LLC. | $137.20 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $136.12 | 2022-2024 | |
| Optinose US, INC. | $122.24 | 2021-2025 | |
| Incyte Corporation | $116.59 | 2022-2025 | Opzelura |
| Amgen INC. | $84.06 | 2021-2025 | |
| Csl Behring | $80.28 | 2021-2024 | Haegarda |
| Kaleo, INC. | $69.97 | 2022-2024 | Auvi-Q |
| Aimmune Therapeutics, INC. | $58.56 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $51.80 | 2025 | Vtama |
| Hikma Pharmaceuticals USA | $47.99 | 2023-2024 | Ryaltris |
| Biocryst US Sales Co., LLC | $47.02 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $44.03 | 2024 | Xolair |
| Alk-Abello, INC | $43.41 | 2021-2023 | Odactra, Grastek, Ragwitek |
| Phathom Pharmaceuticals, INC. | $40.69 | 2023-2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $30.12 | 2025 | Xhance |
| Grifols USA, LLC | $24.92 | 2024 | Xembify |
| Covis Pharma Gmbh | $24.13 | 2022 | |
| Lilly USA, LLC | $22.13 | 2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $21.61 | 2025 | Dawnzera |
| Merck Sharp & Dohme LLC | $15.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Bowyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.